Want to see ELVN full AI Analyst Report?
Enliven Therapeutics (ELVN) Financial Statements
Enliven Therapeutics Financial Overview
Enliven Therapeutics's market cap is currently $3.24B. The company's EPS TTM is $-1.64; its P/E ratio is -26.98; Enliven Therapeutics is estimated to report earnings on November 18, 2026, and the estimated EPS forecast is $-0.45. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -263.00K | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -119.66M | $ -104.55M | $ -83.53M | $ -38.79M | $ -24.76M |
| EBITDA | $ -103.43M | $ -88.47M | $ -71.29M | $ -37.45M | $ -24.63M |
| Net Income | $ -103.69M | $ -89.02M | $ -71.58M | $ -37.66M | $ -24.74M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 462.62M | $ 313.44M | $ 253.15M | $ 75.54M | $ 110.02M |
| Total Assets | $ 476.17M | $ 325.76M | $ 271.87M | $ 83.30M | $ 113.33M |
| Total Debt | $ 399.00K | $ 0.00 | $ 335.00K | $ 323.00K | $ 159.00K |
| Net Debt | $ -98.50M | $ -124.12M | $ -99.81M | $ -75.21M | $ -109.86M |
| Total Liabilities | $ 16.68M | $ 15.91M | $ 25.96M | $ 160.12M | $ 6.47M |
| Stockholders' Equity | $ 459.60M | $ 309.85M | $ 245.91M | $ -76.83M | $ 106.86M |
| Cash Flow | |||||
| Free Cash Flow | $ -70.46M | $ -73.24M | $ -61.42M | $ -32.69M | $ -19.32M |
| Operating Cash Flow | $ -70.30M | $ -73.19M | $ -61.27M | $ -32.08M | $ -19.13M |
| Investing Cash Flow | $ -173.84M | $ -36.00M | $ -148.41M | $ -612.00K | $ -191.00K |
| Financing Cash Flow | $ 218.87M | $ 133.16M | $ 234.29M | $ -1.80M | $ -1.02M |
Currency in USD